Form 4: Lyell CMO David Shook Granted 50,000 Stock Options

Lyell Immunopharma's Chief Medical Officer, David Shook, was granted 50,000 stock options and reported beneficial ownership of 21,900 common shares.

Summary

• Chief Medical Officer David Shook of Lyell Immunopharma, Inc. (LYEL) was granted 50,000 stock options.
• The options have an exercise price of $23.71 per share and expire on February 9, 2036.
• The options vest over time, with 12.5% vesting six months after February 9, 2026, and the remainder vesting monthly at 1/48th of the total shares, contingent on continued service.
• The transaction was made pursuant to a pre-arranged Rule 10b5-1(c) plan.
• Following this transaction, Mr. Shook beneficially owns 21,900 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive compensation practices designed to align management incentives with long-term company performance and shareholder value.

Positives

• The grant of 50,000 stock options aligns management's interests with long-term shareholder value.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned and transparent equity award.

Future Outlook

The granted stock options are subject to a vesting schedule, with 12.5% vesting six months after February 9, 2026, and the remainder vesting monthly over the subsequent 48 months, contingent on the Chief Medical Officer's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants, particularly stock options with multi-year vesting schedules, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to incentivize long-term performance and align executive interests with shareholder returns, a common practice among peers in the competitive life sciences sector.

Comparison to Industry Standards

• The grant of stock options to a Chief Medical Officer is a standard compensation practice in the biotech industry, comparable to similar grants at companies like Moderna, BioNTech, or Gilead Sciences, where executive compensation often includes significant equity components to incentivize innovation and long-term value creation.
• The vesting schedule, with an initial cliff and subsequent monthly vesting, is a common structure designed to retain key talent and ensure sustained commitment, aligning with typical industry benchmarks for executive equity awards.

Related Party Transactions

• The grant of stock options to Chief Medical Officer David Shook constitutes a related party transaction, as it involves an equity award from the company to an executive.

Stakeholder Impact

• Shareholders: The option grant aligns the Chief Medical Officer's financial interests with long-term shareholder value, potentially incentivizing performance that benefits the stock price.
• Employees: Standard executive compensation practices, including equity grants, can set a precedent for broader employee incentive programs.

Next Steps

• Continued service by David Shook to ensure vesting of the stock options.
• Future exercise of options by David Shook, subject to vesting and market conditions.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard compensation practice and does not provide new fundamental information to warrant a change in investment recommendation. It primarily serves to align executive incentives with long-term company performance.

Keywords

Lyell Immunopharma, LYEL, David Shook, Stock Options, Insider Transaction, Form 4, Equity Grant, Chief Medical Officer, Executive Compensation, Vesting Schedule